hidradenitis suppurativa and glp 1 GLP-1 Receptor Agonists Show Promise in GLP-1 RAs show promise in

The ELAD Phase 2b trial of liraglutide, published in Nature Medicine, randomised 204 patients with mild to moderate disease to daily liraglutide or placebo for 52 weeks

Make your fasting journey effortless

Here we review the charts of consecutive patients seen in a medically based autism clinic who underwent a systematic workup for mitochondrial disorders per recently published guidelines, which included screening for fatty-acid metabolism disorders

BPC-157 in Inflammatory Bowel Disease (IBD) In ulcerative colitis and Crohns disease models, BPC-157 has: Reduced mucosal damage and bleeding Lowered inflammation markers Promoted rapid tissue healing Minimized recurrence of flare-ups 4